Engineered microRNA therapeutics

Perspectives in MicroRNA Therapeutics

RNA-based therapeutics hold significant potential as promising treatment options for human disease. In the past 20 years, advances in the RNA field have identified several novel RNAbased therapies that are currently under clinical investigation, including antisense oligonucleotides, small interfering RNA (siRNA), and microRNA. By targeting RNA and modulating human biology at the molecular level...

MicroRNA therapeutics for cardiovascular disease

MicroRNAs (miRNAs) are short, single-stranded, noncoding RNAs that exert their function through annealing with complementary sequences in specific messenger RNAs (mRNAs) to inhibit their translation into proteins. Even though it was only a decade ago that the first human miRNA was discovered, therapeutics to regulate miRNA function are already entering the clinical space. The main reasons for t...

MicroRNA therapeutics in cardiovascular medicine

Cardiovascular diseases are the most common causes of human morbidity and mortality despite significant therapeutic improvements by surgical, interventional and pharmacological approaches in the last decade. MicroRNAs (miRNAs) are important and powerful mediators in a wide range of diseases and thus emerged as interesting new drug targets. An array of animal and even human miRNA-based therapeut...

Adnectins: engineered target-binding protein therapeutics

Adnectins™ are a new family of therapeutic proteins based on the 10th fibronectin type III domain, and designed to bind with high affinity and specificity to therapeutically relevant targets. Adnectins share with antibody variable domains a beta-sheet sandwich fold with diversified loops, but differ from antibodies in primary sequence and have a simpler, single-domain structure without disulfid...

Multifunctional Therapeutics using Engineered Plant Virus Nanoparticles